Scientific article

English

Glatiramer acetate treatment negatively regulates type I interferon signaling

ContributorsMolnarfi, Nicolas

; Prod'homme, Thomas; Schulze-Topphoff, Ulf; Spencer, Collin M; Weber, Martin S; Patarroyo, Juan C; Lalive d'Epinay, Patrice; Zamvil, Scott S

Published inNeurology® neuroimmunology & neuroinflammation, vol. 2, no. 6, e179

Publication date2015

Abstract

Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-mediated M2 monocyte polarization.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques

Research groups

Scléroses en plaques, neuroimmunologie, encéphalite autoimmune expérimentale (843)

Citation (ISO format)

MOLNARFI, Nicolas et al. Glatiramer acetate treatment negatively regulates type I interferon signaling. In: Neurology® neuroimmunology & neuroinflammation, 2015, vol. 2, n° 6, p. e179. doi: 10.1212/NXI.0000000000000179

Article (Published version)

Identifiers

PID : unige:89956
DOI : 10.1212/NXI.0000000000000179
PMID : 26601118

Journal ISSN2332-7812

478views

1downloads

Creation30/11/2016 14:38:00

First validation30/11/2016 14:38:00

Update15/03/2023 01:06:01

Status update15/03/2023 01:06:00

Last indexation31/10/2024 05:26:30